Summary

Report Scope
The report examines and segments the global cardiovascular drugs market by disease area, drug class, and route of administration. It also provides insights into key emerging trends and potential growth drivers. The study focuses on disease areas, including hypertension, hyperlipidemia, thrombosis, cardiac failure therapy, and other disease areas. By drug class, the market is segmented into antithrombotics, antihypertensives, lipid-lowering agents, antiarrhythmics, alpha blockers, and other drug classes. By route of administration, the market is divided into oral, intravenous, subcutaneous, and other routes of administration.
The report encompasses a comprehensive regional analysis across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA). It examines how the adoption of AI affects the cardiovascular drugs industry and broader market dynamics, including key drivers, challenges, and emerging trends. It also includes patent analysis and clinical trials of the cardiovascular drugs. The study concludes with the analysis of major companies and their offerings.
It includes global revenue ($ million) for the base year of 2024, estimated for 2025, and forecast data for 2026 through 2030.
Report Includes
- 114 data tables and 48 additional tables
- An analysis of the global markets for cardiovascular drugs
- Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by disease area, drug class, route of administration and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impact of macroeconomic variables
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Patent review, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Company profiles of major players within the industry, including Lilly USA LLC., Bristol-Myers Squibb Co., AstraZeneca, Boehringer Ingelheim International GmbH, and Novartis AG

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Current Market Overview
Future Outlook
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Market
Impact of the Ukraine-Russia War
Epidemiological Trends
Inflation and Currency Fluctuations
Porter’s Five Forces Analysis
Potential of New Entrants: Low
Bargaining Power of Suppliers: Moderate
Bargaining Power of Buyers: High
Threat of Substitutes: Moderate
Competition in the Industry: High
Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Rising Prevalence of Cardiovascular Diseases
Improved Disease Diagnosis and Screening
Advances in Drug Development
Market Restraints
Patent Expirations and Generic Competition
Pricing and Reimbursement Issues
Delays in Regulatory Approvals
Market Opportunities
Development of Novel Drug Classes
Rising Demand for Personalized Medicine
Chapter 4 Regulatory Landscape
Regulatory Framework
U.S.
Europe
India
Australia
Japan
Chapter 5 Emerging Technologies and Patent Analysis
Overview
Emerging Technologies
Artificial Intelligence (AI) and Machine Learning (ML)
Nanoparticle-Mediated Drug Delivery
Gene Therapy
RNA-Based Therapeutics
Intracoronary Drug Delivery
Patent Analysis
Key Takeaways
Patents by Year
Patents by Leading Jurisdiction
Patents by Leading Inventor
Clinical Trials Analysis
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Cardiovascular Drugs Market, by Disease Area
Key Takeaways
Hypertension
Hyperlipidemia
Thrombosis
Cardiac Failure Therapy
Other Disease Areas
Global Cardiovascular Drugs Market, by Drug Class
Key Takeaways
Antithrombotics
Antihypertensives
Lipid-Lowering Agents
Antiarrhythmics
Alpha Blockers
Other Drug Classes
Global Cardiovascular Drugs Market, by Route of Administration
Key Takeaways
Oral
Intravenous
Subcutaneous
Other Routes of Administration
Geographic Breakdown
Global Cardiovascular Drugs Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Industry Structure
Company Share Analysis for Cardiovascular Drugs Market
Strategic Analysis
Chapter 8 Appendix
Methodology
Sources
Abbreviations
Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
DAIICHI SANKYO CO. LTD.
GILEAD SCIENCES INC.
HIKMA PHARMACEUTICALS PLC
JOHNSON & JOHNSON
LILLY USA LLC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI
UNITED THERAPEUTICS CORP.
Emerging Startups/Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for Cardiovascular Drugs, by Region, Through 2030
Table 1 : Global and Regional Age Standardization CVD Mortality Rates, 2021
Table 2 : Global Cardiovascular Disease Statistics: Burden and Mortality Trends, 2023
Table 3 : Expected Patent Expiry Drugs, by 2026
Table 4 : Patents Granted for Cardiovascular Drugs, by Year, 2022-2026*
Table 5 : Patents Granted for Cardiovascular Drugs, by Top Jurisdiction, 2022-2026*
Table 6 : Patents Granted for Cardiovascular Drugs, by Top Inventor, 2022-2026*
Table 7 : Drug Clinical Trials in the Cardiovascular Drugs Market, 2022-2026
Table 8 : Global Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 9 : Global Market for Cardiovascular Drugs for Hypertension, by Region, Through 2030
Table 10 : Global Market for Cardiovascular Drugs for Hyperlipidemia, by Region, Through 2030
Table 11 : Global Market for Cardiovascular Drugs for Thrombosis, by Region, Through 2030
Table 12 : Global Market for Cardiovascular Drugs for Cardiac Failure Therapy, by Region, Through 2030
Table 13 : Global Market for Cardiovascular Drugs for Other Disease Areas, by Region, Through 2030
Table 14 : Global Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 15 : Global Market for Antithrombotic Drugs, by Region, Through 2030
Table 16 : Global Market for Antihypertensive Drugs, by Region, Through 2030
Table 17 : Global Market for Lipid-Lowering Agents, by Region, Through 2030
Table 18 : Global Market for Antiarrhythmic Drugs, by Region, Through 2030
Table 19 : Global Market for Alpha Blocker Drugs, by Region, Through 2030
Table 20 : Global Market for Other Drug Classes, by Region, Through 2030
Table 21 : Global Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 22 : Global Market for Oral Administration for Cardiovascular Drugs, by Region, Through 2030
Table 23 : Global Market for Intravenous Administration for Cardiovascular Drugs, by Region, Through 2030
Table 24 : Global Market for Subcutaneous Administration for Cardiovascular Drugs, by Region, Through 2030
Table 25 : Global Market for Other Routes of Administration, by Region, Through 2030
Table 26 : Global Market for Cardiovascular Drugs, by Region, Through 2030
Table 27 : North American Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 28 : North American Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 29 : North American Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 30 : North American Market for Cardiovascular Drugs, by Country, Through 2030
Table 31 : U.S. Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 32 : U.S. Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 33 : U.S. Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 34 : Canadian Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 35 : Canadian Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 36 : Canadian Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 37 : Mexican Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 38 : Mexican Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 39 : Mexican Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 40 : European Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 41 : European Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 42 : European Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 43 : European Market for Cardiovascular Drugs, by Country, Through 2030
Table 44 : German Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 45 : German Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 46 : German Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 47 : U.K. Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 48 : U.K. Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 49 : U.K. Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 50 : French Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 51 : French Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 52 : French Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 53 : Italian Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 54 : Italian Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 55 : Italian Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 56 : Spanish Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 57 : Spanish Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 58 : Spanish Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 59 : Rest of European Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 60 : Rest of European Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 61 : Rest of European Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 62 : Asia-Pacific Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 63 : Asia-Pacific Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 64 : Asia-Pacific Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 65 : Asia-Pacific Market for Cardiovascular Drugs, by Country, Through 2030
Table 66 : Chinese Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 67 : Chinese Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 68 : Chinese Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 69 : Japanese Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 70 : Japanese Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 71 : Japanese Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 72 : Indian Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 73 : Indian Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 74 : Indian Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 75 : South Korean Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 76 : South Korean Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 77 : South Korean Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 78 : Australian Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 79 : Australian Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 80 : Australian Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 81 : Rest of Asia-Pacific Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 82 : Rest of Asia-Pacific Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 83 : Rest of Asia-Pacific Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 84 : MEA Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 85 : MEA Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 86 : MEA Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 87 : MEA Market for Cardiovascular Drugs Market, by Country, Through 2030
Table 88 : Middle East Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 89 : Middle East Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 90 : Middle East Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 91 : African Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 92 : African Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 93 : African Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 94 : South American Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 95 : South American Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 96 : South American Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 97 : South American Market for Cardiovascular Drugs, by Country, Through 2030
Table 98 : Brazilian Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 99 : Brazilian Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 100 : Brazilian Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 101 : Argentine Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 102 : Argentine Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 103 : Argentine Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 104 : Rest of South America Market for Cardiovascular Drugs, by Disease Area, Through 2030
Table 105 : Rest of South America Market for Cardiovascular Drugs, by Drug Class, Through 2030
Table 106 : Rest of South America Market for Cardiovascular Drugs, by Route of Administration, Through 2030
Table 107 : Strategic Initiatives for Cardiovascular Drugs Market, 2024 and 2025
Table 108 : Report Information Sources
Table 109 : Abbreviations Used in the Report
Table 110 : Amgen Inc.: Company Snapshot
Table 111 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 112 : Amgen Inc.: Product Portfolio
Table 113 : Amgen Inc.: News/Key Developments, 2025
Table 114 : AstraZeneca: Company Snapshot
Table 115 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 116 : AstraZeneca: Product Portfolio
Table 117 : AstraZeneca: News/Key Developments, 2024
Table 118 : Bayer AG: Company Snapshot
Table 119 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 120 : Bayer AG: Product Portfolio
Table 121 : Bayer AG: News/Key Developments, 2024 and 2025
Table 122 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 123 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
Table 124 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 125 : Bristol-Myers Squibb Co.: Company Snapshot
Table 126 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 127 : Bristol-Myers Squibb Co.: Product Portfolio
Table 128 : Bristol-Myers Squibb Co.: News/Key Developments, 2024 and 2025
Table 129 : Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 130 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 131 : Daiichi Sankyo Co. Ltd.: Product Portfolio
Table 132 : Gilead Sciences Inc.: Company Snapshot
Table 133 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 134 : Gilead Sciences Inc.: Product Portfolio
Table 135 : Hikma Pharmaceuticals PLC: Company Snapshot
Table 136 : Hikma Pharmaceuticals PLC: Financial Performance, FY 2023 and 2024
Table 137 : Hikma Pharmaceuticals PLC: Product Portfolio
Table 138 : Hikma Pharmaceuticals PLC: News/Key Developments, 2024
Table 139 : Johnson & Johnson: Company Snapshot
Table 140 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 141 : Johnson & Johnson: Product Portfolio
Table 142 : Lilly USA LLC.: Company Snapshot
Table 143 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 144 : Lilly USA LLC.: Product Portfolio
Table 145 : Merck & Co. Inc.: Company Snapshot
Table 146 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 147 : Merck & Co. Inc.: Product Portfolio
Table 148 : Merck & Co. Inc.: News/Key Developments, 2024 and 2025
Table 149 : Novartis AG: Company Snapshot
Table 150 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 151 : Novartis AG: Product Portfolio
Table 152 : Pfizer Inc.: Company Snapshot
Table 153 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 154 : Pfizer Inc.: Product Portfolio
Table 155 : Sanofi: Company Snapshot
Table 156 : Sanofi: Financial Performance, FY 2023 and 2024
Table 157 : Sanofi: Product Portfolio
Table 158 : United Therapeutics Corp.: Company Snapshot
Table 159 : United Therapeutics Corp.: Financial Performance, FY 2023 and 2024
Table 160 : United Therapeutics Corp.: Product Portfolio
Table 161 : List of a Few Emerging Startups in the Global Cardiovascular Drugs MarketList of Figures
Summary Figure : Global Market Shares for Cardiovascular Drugs, by Region, 2024
Figure 1 : Spending on Drugs Purchased Through 340B Program, 2021
Figure 2 : Porter’s Five Forces Analysis: Global Cardiovascular Drugs Market
Figure 3 : Market Dynamics of Cardiovascular Drugs
Figure 4 : Global Market Shares for Cardiovascular Drugs, by Disease Area, 2024
Figure 5 : Global Market Shares for Cardiovascular Drugs for Hypertension, by Region, 2024
Figure 6 : Global Market Shares for Cardiovascular Drugs for Hyperlipidemia, by Region, 2024
Figure 7 : Global Market Shares for Cardiovascular Drugs for Thrombosis, by Region, 2024
Figure 8 : Global Market Shares for Cardiovascular Drugs for Cardiac Failure Therapy, by Region, 2024
Figure 9 : Global Market Shares for Cardiovascular Drugs for Other Disease Areas, by Region, 2024
Figure 10 : Global Market Shares for Cardiovascular Drugs, by Drug Class, 2024
Figure 11 : Global Market Shares for Antithrombotic Drugs, by Region, 2024
Figure 12 : Global Market Shares for Antihypertensive Drugs, by Region, 2024
Figure 13 : Global Market Shares for Lipid-Lowering Agents, by Region, 2024
Figure 14 : Global Market Shares for Antiarrhythmic Drugs, by Region, 2024
Figure 15 : Global Market Shares for Alpha Blocker Drugs, by Region, 2024
Figure 16 : Global Market Shares for Other Drug Classes, by Region, 2024
Figure 17 : Global Market Shares for Cardiovascular Drugs, by Route of Administration, 2024
Figure 18 : Global Market Shares for Oral Administration for Cardiovascular Drugs, by Region, 2024
Figure 19 : Global Market Shares for Intravenous Administration for Cardiovascular Drugs, by Region, 2024
Figure 20 : Global Market Shares for Subcutaneous Administration for Cardiovascular Drugs, by Region, 2024
Figure 21 : Global Market Shares for Other Routes of Administration, by Region, 2024
Figure 22 : Global Market Shares for Cardiovascular Drugs, by Region, 2024
Figure 23 : North American Market Shares for Cardiovascular Drugs, by Country, 2024
Figure 24 : European Market Shares for Cardiovascular Drugs, by Country, 2024
Figure 25 : Asia-Pacific Market Shares for Cardiovascular Drugs, by Country, 2024
Figure 26 : MEA Market Shares for Cardiovascular Drugs, by Country, 2024
Figure 27 : South American Market Shares for Cardiovascular Drugs, by Country, 2024
Figure 28 : Global Market Shares for Cardiovascular Drugs, by Major Companies, 2024
Figure 29 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 30 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 31 : ASTRAZENECA: Revenue Share, by Business Unit, FY 2024
Figure 32 : ASTRAZENECA: Revenue Share, by Country/Region, FY 2024
Figure 33 : Bayer AG: Revenue Share, by Business Unit, FY 2024
Figure 34 : Bayer AG: Revenue Share, by Country/Region, FY 2024
Figure 35 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2024
Figure 36 : Boehringer Ingelheim International GmbH: Revenue Share, by Country/Region, FY 2024
Figure 37 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 38 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 39 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 40 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 41 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 42 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 43 : Hikma Pharmaceuticals PLC: Revenue Share, by Business Unit, FY 2024
Figure 44 : Hikma Pharmaceuticals PLC: Revenue Share, by Country/Region, FY 2024
Figure 45 : Johnson & Johnson: Revenue Share, by Business Unit, FY 2024
Figure 46 : Johnson & Johnson: Revenue Share, by Country/Region, FY 2024
Figure 47 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 48 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
Figure 49 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
Figure 50 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 51 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 52 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 53 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 54 : SANOFI: Revenue Share, by Country/Region, FY 2024
Figure 55 : United Therapeutics Corp.: Revenue Share, by Country/Region, FY 2024